Research At a Glance
- Research Category
- Tissue Repair & Recovery Research
- Peptide Length
- Blend: 15 aa (BPC-157) + 43 aa fragment (TB-500)
- Purity
- ≥ 99% (HPLC, per component)
- Published Studies
- 1,200+ indexed (combined literature)
- Storage
- Lyophilized: 2–8 °C, protected from light. Reconstituted: 2–8 °C, use within 30 days.
Published-study figures are approximate PubMed result counts and indicate the volume of available literature only. Purity reflects third-party analytical testing on the corresponding lot; see the Quality Assurance Center for lot-matched certificates.
Overview
This blend combines two of the most-studied tissue-repair research peptides: BPC-157, a synthetic pentadecapeptide (15 amino acids) derived from a protective fragment of human gastric juice protein, and TB-500, a synthetic peptide based on the actin-binding domain of Thymosin Beta-4, a 43-amino-acid protein found throughout human tissue. The two compounds are studied together because their proposed mechanisms are complementary rather than overlapping: BPC-157 research centers on vascular and cytoprotective signaling, while TB-500 research centers on actin cytoskeleton regulation and cell migration. Combined-use protocols are a common feature of tissue-repair and regenerative-model research, though most published data evaluate each peptide independently rather than as a fixed combination.
Citation
Sikiric P., et al. (2024). Pharmaceuticals.
History
BPC-157 was first described in 1993 by Predrag Sikiric and colleagues at the University of Zagreb, isolated from a gastric juice protein fraction and named for its “body protection compound” activity — its defining early property was gastroprotection against ulcers, restraint stress, and chemical injury in rodent models, with research since expanding into vascular, neurological, and musculoskeletal systems. TB-500 traces to Thymosin Beta-4, first characterized as the primary G-actin sequestering protein in mammalian cells; its actin-binding domain (the LKKTETQ sequence) was identified in the early 2000s as necessary and sufficient for the protein’s angiogenic and wound-healing activity, leading to synthetic fragments studied under the name TB-500.
Citation
Sikiric P., et al. (1993). Journal de Physiologie (Paris).
Molecular Structure
| BPC-157 CAS # | 137525-51-0 |
|---|---|
| BPC-157 Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| BPC-157 Molecular Weight | 1419.53 g/mol |
| BPC-157 PubChem CID | 9941957 |
| TB-500 CAS # | 77591-33-4 |
| TB-500 Molecular Formula | C₂₁₂H₃₅₀N₅₆O₇₈S |
| TB-500 Molecular Weight | 4963.5 g/mol |
| TB-500 PubChem CID | 16130262 |
Research Findings
This combination has been studied across gastrointestinal, vascular, musculoskeletal, and dermal wound-healing models, with each component contributing a distinct proposed mechanism.
Key Areas of Research
- Gastrointestinal — BPC-157 gastroprotection, anastomosis and fistula healing, inflammatory bowel disease models
- Vascular — BPC-157 angiogenesis and vascular recruitment; TB-500 endothelial cell migration and VEGF signaling
- Musculoskeletal — Tendon, ligament, and muscle injury models for both compounds
- Cellular/dermal — TB-500 actin cytoskeleton regulation, keratinocyte migration, dermal wound closure
Summary
Together, the pairing reflects two distinct but complementary tissue-repair research mechanisms — BPC-157’s broad cytoprotective and angiogenic signaling alongside TB-500’s cell-migration and actin-regulatory activity. Both compounds have an extensive rodent and in vitro literature; the combined-use rationale is grounded in their non-overlapping pathways, though direct combination-arm studies remain limited compared to each compound’s individual literature.
Citation
Sosne G., et al. (2010). FASEB Journal.
Further Reading
Search peer-reviewed literature on PubMed — BPC-157 and TB-500 tissue repair research .
References
- Sikiric P., Petek M., Rucman R., et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal de Physiologie (Paris).
- Sikiric P., Boban Blagaic A., Strbe S., et al. (2024). The Stable Gastric Pentadecapeptide BPC 157: Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals.
- Philp D., Huff T., Gho Y.S., Hannappel E., Kleinman H.K. (2003). The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal.
- Sosne G., Qiu P., Goldstein A.L., et al. (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal.
Certificate of Analysis
Every lot is independently tested and lot-matched. View Certificates of Analysis